WealthCare Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

WealthCare Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.4M	Buy	+58,974	New	+$3.39M	1.41%	17

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

WealthCare Asset Management's BMY Position: Q2 2026 in Review

WealthCare Asset Management opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 58,974 shares worth $3.4M. The stake represents 1.41% of the portfolio and ranks #17 among its holdings.

2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

WealthCare Asset Management held 58,974 shares of Bristol-Myers Squibb worth $3.4M as of Q2 2026.
Bristol-Myers Squibb was a new WealthCare Asset Management position in Q2 2026.
Bristol-Myers Squibb made up 1.41% of WealthCare Asset Management's portfolio in Q2 2026, its #17 holding.
2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on WealthCare Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.